Plus Therapeutics (NASDAQ:PSTV) Coverage Initiated at Lake Street Capital

Analysts at Lake Street Capital assumed coverage on shares of Plus Therapeutics (NASDAQ:PSTV) in a research report issued on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $2.00 price target on the stock.

Other equities analysts also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $1.00 price objective (down previously from $2.00) on shares of Plus Therapeutics in a research note on Friday, January 23rd. D. Boral Capital reduced their target price on Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, January 22nd. Zacks Research downgraded Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. Finally, Ascendiant Capital Markets decreased their price objective on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a report on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.80.

Plus Therapeutics Trading Up 0.7%

PSTV stock opened at $0.24 on Tuesday. Plus Therapeutics has a twelve month low of $0.16 and a twelve month high of $2.31. The company’s 50 day moving average is $0.48 and its two-hundred day moving average is $0.53. The stock has a market cap of $33.63 million, a P/E ratio of -0.13 and a beta of 0.89.

Institutional Trading of Plus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Altium Capital Management LLC purchased a new position in Plus Therapeutics during the third quarter worth about $628,000. Scientech Research LLC purchased a new position in shares of Plus Therapeutics during the 3rd quarter worth approximately $100,000. Jane Street Group LLC purchased a new position in shares of Plus Therapeutics during the 2nd quarter worth approximately $41,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics in the 3rd quarter valued at approximately $46,000. Hedge funds and other institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.